Non-clinical safety considerations to support paediatric drug development - a regulatory update

被引：0
|
作者：
Baldrick, P. [1 ]
机构：
[1] Covance UK, Harrogate, England
来源：
TOXICOLOGY LETTERS | 2018年 / 295卷
关键词：
D O I：
10.1016/j.toxlet.2018.06.1159
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
S15-04
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [1] Non-clinical development of cancer vaccines: Regulatory considerations
    Chabicovsky, M
    Ryle, P
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 44 (03) : 226 - 237
  • [2] Non-clinical development of anticancer drugs: Safety considerations
    Colombo, Paolo
    Cattoni, Marina
    Di Gallo, Guido
    Pulci, Romana
    Brughera, Marco
    [J]. TOXICOLOGY LETTERS, 2008, 180 : S151 - S152
  • [3] EEG in non-clinical drug safety assessments: Current and emerging considerations
    Authier, Simon
    Delatte, Marcus S.
    Kallman, Mary-Jeanne
    Stevens, Joanne
    Markgraf, Carrie
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2016, 81 : 274 - 285
  • [4] Regulatory science for the safety evaluation to risk assessment/management in non-clinical drug research and development
    Horii, Ikuo
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 52P - 52P
  • [5] Value of non-clinical QT-related assays to support drug discovery, development, and regulatory approval: case studies
    Valentin, J-P
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 8 - 8
  • [6] Exploratory clinical trials: A non-clinical drug safety perspective
    Weaver, R. J.
    [J]. TOXICOLOGY LETTERS, 2011, 205 : S2 - S2
  • [7] Considerations for non-clinical safety studies of therapeutic peptide vaccines
    Matsumoto, Mineo
    Komatsu, Shinichi
    Tsuchimoto, Mayumi
    Matsui, Hajime
    Watanabe, Kazuto
    Nakamura, Kazuichi
    Amakasu, Kohei
    Ito, Kanako
    Fueki, Osamu
    Sawada, Jun-ichi
    Maki, Kazushige
    Onodera, Hiroshi
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2014, 70 (01) : 254 - 260
  • [8] Pharmacogenetics in drug development: Regulatory and clinical considerations
    Hall, ST
    Abbott, N
    Schmith, G
    Brazell, C
    [J]. DRUG DEVELOPMENT RESEARCH, 2004, 62 (02) : 102 - 111
  • [9] Is the current non-clinical drug development safety paradigm effective for assessing cardiovascular liabilities?
    Roche, Brian
    Ross, John
    Obejero-Paz, Carlos A.
    Kramer, James
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2019, 99
  • [10] Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals
    Korde, Aruna
    Mikolajczak, Renata
    Kolenc, Petra
    Bouziotis, Penelope
    Westin, Hadis
    Lauritzen, Mette
    Koole, Michel
    Herth, Matthias Manfred
    Bardies, Manuel
    Martins, Andre F.
    Paulo, Antonio
    Lyashchenko, Serge K.
    Todde, Sergio
    Nag, Sangram
    Lamprou, Efthimis
    Abrunhosa, Antero
    Giammarile, Francesco
    Decristoforo, Clemens
    [J]. EJNMMI RADIOPHARMACY AND CHEMISTRY, 2022, 7 (01)
12345